SP和XELOX方案治疗晚期胃癌的临床疗效观察  

Clinical Study of SP Combined with Cisplatin and XELOX For Advanced Gastric Cancer

作　　者：刘坤[1] 王羽丰[1] 江波[1] 杨梅[1] 

机构地区：[1]云南省肿瘤医院干疗科,650118

出　　处：《实用癌症杂志》2013年第2期155-157,178,共4页The Practical Journal of Cancer

摘　　要：目的比较SP方案(替吉奥联合顺铂)与XELOX方案(奥沙利铂联合希罗达)治疗晚期胃癌的疗效及安全性。方法对32例晚期胃癌患者采用SP方案治疗,并与XELOX方案(30例)进行疗效比较。结果 SP方案组总有效率为50.0%(16/32),XELOX方案组总有效率为43.3%(13/30),两组间比较无显著性差异(P>0.05);SP方案组骨髓抑制发生率较XELOX组高,而手足综合征、神经毒性发生率较XELOX组低,两组比较差异有统计学意义(P<0.05)。结论 SP方案和XELOX方案对晚期胃癌的疗效相近,毒副作用可耐受,临床中可根据患者年龄、一般状况及其他预后因素个体化选择化疗方案。Objective To compare the efficacy and toxicity of the regimen of SP （S-1 and cisplatin） with XELOX （ox- aliplatin and xeloda） in treatment of patients with advanced gastric cancer. Methods Data of patients with advanced gastric cancer treated with SP（ n = 32） were compared with those treated with XELOX（ n = 30）. Results The overall response rate was 50.0% in SP group and 43.3% in XELOX group （P 〉0.05）. The main complications were myelosuppression in SP group and hand-foot syndrome ,neurosensory in XELOX group （P 〈 0.05 ）. Conclusion SP regimen is as effective as XELOX in the treat- ment of advanced gastric cancer with tolerable toxicities. We should choose individual chemotherapy regimens by patient, stage, peformas status and other prognostic factors.

关 键 词：晚期胃癌 SP(替吉奥联合顺铂) XELOX(奥沙利铂联合希罗达) 

分 类 号：R735.2[医药卫生—肿瘤]